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Abstract
Since in most tumors multiple signaling pathways are 
involved, many of the inhibitors in clinical development 
are designed to affect a wide range of targeted kinases. 
The most important tyrosine kinase families in the de-
velopment of tyrosine kinase inhibitors are the ABL, 
SCR, platelet derived growth factor, vascular endothelial 
growth factor receptor and epidermal growth factor re-
ceptor families. Both multi-kinase inhibitors and single-
kinase inhibitors have advantages and disadvantages, 
which are related to potential resistance mechanisms, 
pharmacokinetics, selectivity and tumor environment. In 
different malignancies various tyrosine kinases are mutat-
ed or overexpressed and several resistance mechanisms 
exist. Pharmacokinetics is influenced by interindividual 
differences and differs for two single targeted inhibitors 
or between patients treated by the same tyrosine kinase 
inhibitor. Different tyrosine kinase inhibitors have various 
mechanisms to achieve selectivity, while differences in 
gene expression exist between tumor and stromal cells. 
Considering these aspects, one type of inhibitor can gen-
erally not be preferred above the other, but will depend 
on the specific genetic constitution of the patient and 
the tumor, allowing personalized therapy. The most ef-
fective way of cancer treatment by using tyrosine kinase 
inhibitors is to consider each patient/tumor individually 
and to determine the strategy that specifically targets 
the consequences of altered (epi)genetics of the tumor. 
This strategy might result in treatment by a single multi 
kinase inhibitor for one patient, but in treatment by a 
couple of single kinase inhibitors for other patients. 
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
One of  the most common treatments for cancer includes 
the use of  cytotoxic chemotherapeutics. However, this 
type of  treatment, which is based on the difference in cell 
division rate between normal and cancer cells, is accompa-
nied by several side effects due to the general vulnerability 
of  cells to cytotoxic therapeutics. In order to reduce or 
change these side-effects, targeted therapies, which spe-
cifically attack signaling pathways driving the growth of  
tumors, are being developed. In addition to different side-
effects, these therapeutics may result in a higher efficacy. 
In practice, they may result in activity against other tumors. 
An important mechanism in signal transduction pathways 
in cells is protein phosphorylation, which is carried out by 
protein kinases. These kinases regulate the fundamental 
processes of  proliferation, differentiation, migration, me-
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tabolism and anti-apoptotic signalling of  the cell. 
The most important protein kinases are the serine/
threonine and tyrosine kinases, which are characterized 
by their ability to catalyze the phosphorylation of  ser-
ine/threonine or tyrosine amino acid residues in proteins, 
respectively. This paper will mostly focus on tyrosine 
kinases. Two classes of  tyrosine kinases are distinguished: 
receptor tyrosine kinases and cellular tyrosine kinases. 
Receptor tyrosine kinases consist of  an extracellular li-
gand binding domain, a transmembrane domain and an 
intracellular catalytic domain (Figure 1). Dimerization of  
two receptor tyrosine kinases upon ligand binding results 
in autophosphorylation of  the tyrosine residues of  the 
intracellular catalytic domains, which leads to an active 
conformation and subsequent activation of  the signal 
transduction cascade within the cell. In this downstream 
signal transduction cascade, cellular tyrosine kinases play a 
primary role. The latter are located in the cytoplasm or in 
the nucleus[1]. In Figure 1, an example of  signal transduc-
tion pathways by protein phosphorylation by epidermal 
growth factor receptor (EGFR) signalling is given. 
Because of  their important effects on cells, tyrosine 
kinases are highly regulated. When these kinases become 
constitutively activated and independent of  ligands by 
mutations or over-expression, cancer develops by unregu-
lated cell proliferation amongst other mechanisms. For this 
reason, tyrosine kinase inhibitors can serve as anticancer 
agents by interfering with this unregulated process[2]. Tyro-
sine kinase inhibitors are divided in monoclonal antibodies 
and small molecule tyrosine kinase inhibitors (TKIs). The 
latter are the subject of  this paper. TKIs appear to stabilize 
tumor progression in many tumor types, have minimal or 
different side effects compared to cytotoxic chemothera-
peutic agents and are often synergistic in combination with 
radiotherapy and/or chemotherapy[3]. A current trend in the 
development of  tyrosine kinase inhibitors is the assumption 
that multi targeted therapy, which targets several signaling 
pathways simultaneously, is more effective than single tar-
geted therapy. Single targeted therapies have shown activ-
ity for only a few indications and most solid tumors show 
deregulation of  multiple signaling pathways. For example, 
the combination of  a vascular endothelial growth factor 
receptor (VEGFR) inhibitor and platelet derived growth 
factor receptor (PDGFR) inhibitor results in a cumulative 
antitumor efficacy[4].
The hypothesis that altered signal transduction path-
ways are most effectively inhibited by multi-kinase inhibi-
tors leads to the subsequent question: is it better to use 
several single inhibitors or single inhibitors with multiple 
effects? The first part of  this paper deals with several ty-
rosine kinase inhibitors that are in clinical development or 
are recently approved. Subsequently, issues that might be 
important in addressing the question “what’s better: multi 
single or a single multi?” will be discussed. 
TYROSINE KINASE INHIBITORS IN 
CLINICAL DEVELOPMENT
In the human genome, at least 90 tyrosine kinases have 
been identified[5]. Fifty-six receptor tyrosine kinases 
are expressed, which can be subdivided in 19 families 
(AATYK, ALK, AXL, DDR, EGFR, EPH, FGFR, 
INSR, MET, MUSK, PDGFR, PTK7, RET, ROR, ROS, 
RYK, TIE, TRK and VEGFR family)[6]. In addition, 32 
cellular tyrosine kinases are expressed, which can be sub-
divided in 11 families [ABL, ACK, CSK, focal adhesion 
kinase (FAK), FES, FRK, JAK, SRC-A, SRC-B, TEC 
and SYK family]. Among these, the ABL, SCR, EGFR, 
PDGFR and VEGFR families have been the primary 
targets for development of  tyrosine kinase inhibitors. 
Tyrosine kinase inhibitors are being developed to block 
abnormal signalling of  signal transduction pathways that 
are involved in cellular growth and proliferation. While 
some tyrosine kinase inhibitors specifically inhibit one or 
two tyrosine kinases, most of  the tyrosine kinase inhibitors 
are designed to inhibit more tyrosine kinases in multiple 
signalling pathways. Some tyrosine kinase inhibitors of  the 
most important cellular and receptor tyrosine kinase fami-
lies will be discussed, as well as several approved tyrosine 
kinase inhibitors and tyrosine kinase inhibitors in develop-
ment.
Cellular tyrosine kinase inhibitors
Many tyrosine kinase inhibitors are designed to target the 
fusion protein Bcr-Abl and members of  the SRC tyrosine 
kinase family. In addition, several tyrosine kinase inhibi-
tors in preclinical development are designed to target the 
JAK tyrosine kinase family. A few novel tyrosine kinase 
inhibitors are in preclinical development for the less well-
known cellular tyrosine kinases. An example is piceatannol 
that is targeted against ZAP70, a member of  the SYK 
tyrosine kinase family[7]. In Table 1, an overview is given 
of  approved tyrosine kinase inhibitors and tyrosine kinase 
inhibitors in development that target the cellular tyrosine 
kinase families ABL, SRC and JAK.
The ABL family: The most important cellular target for 
tyrosine kinase inhibitor development has been the fusion 
protein Bcr-Abl, which is the responsible protein for the 
cancer types chronic myeloid leukemia (CML) and B-cell 
acute lymphoblastic leukemia (B-ALL)[8]. The approved ty-
rosine kinase inhibitor imatinib mesylate (STI571, Gleevec) 
induces complete response in 91% of  chronic phase CML 
patients. However, in later stages of  the disease resistance 
is often experienced[9]. Nilotinib (AMN107) and dasatinib 
(BMS354825) are designed to overcome imatinib resis-
tance in CML. Nilotinib is a selective Bcr-Abl inhibitor, 
which is more potent (20 fold) than imatinib against wild-
type Bcr-Abl and is also active against 32 of  33 (except for 
T315I) imatinib-resistant Bcr-Abl mutants. The inhibitor 
has been evaluated in phase Ⅰ and Ⅱ studies in imatinib-
resistant CML and phase Ⅰ studies in ALL[10,11] and has 
recently been approved[12], along with dasatinib, which is a 
dual inhibitor of  both Bcr-Abl and SRC, which reversed 
14 of  15 imatinib-resistant mutants[13]. Another promising 
dual Bcr-Abl/SRC inhibitor is PD166326, which shows 
100-fold more potency than imatinib and may also reverse 
acquired resistance to imatinib[14,15]. 
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Receptor tyrosine kinase inhibitors
Most tyrosine kinase receptor inhibitors are designed to 
target the EGFR, PDGFR and VEGFR tyrosine kinase 
families. A few receptor tyrosine kinase inhibitors target-
ing tyrosine kinase receptors that are suggested to be rela-
tively less important are also being developed. Examples 
are the MET inhibitor PHA-665752 and the IGF1R in-
hibitors AG1024 and picropodophyllin. These inhibitors, 
however, are still in the preclinical phase. 
An overview of  single-targeted and multi-targeted 
EGFR tyrosine kinase inhibitors is given in Table 2.
The EGFR family: Receptor tyrosine kinases play an 
important role in almost all types of  cancer[16]. The EGFR 
family consists of  the tyrosine kinase receptors EGFR 
(ErbB1, Her1), ErbB2 (Her2), ErbB3 (Her3) and ErbB4 
(Her4). The activation of  these kinases results in deregula-
tion of  cell growth, avoidance of  apoptosis and angiogen-
esis in epithelial malignancies[17,18]. EGFR mutations play 
an important role in non-small cell lung cancer (NSCLC), 
while several mutations enhance the sensitivity to EGFR 
tyrosine kinase inhibitors gefitinib and erlotinib[19,20]. The 
tyrosine kinase inhibitor gefitinib inhibits mutated EGFR 
and is registered for treatment of  NSCLC. Gefitinib is ac-
tive in patients who have mutations in the EGFR kinase 
domain and to a lesser extent EGFR amplification, which 
corresponds with 10% of  the patient group[20,21]. In the 
IPASS study patients were randomized to gefitinib alone 
or docetaxel and carboplatin. Molecular analysis for about 
a third of  the patients suggested that the benefit of  gefi-
tinib was limited to patients with EGFR mutations with 
a progression free survival of  9.5 mo and those treated 
with docetaxel-carboplatin (6.3 mo) (P < 0.001). Gefitinib 
treatment was detrimental for patients without muta-
tions (progression-free survival less than 3 mo)[22]. When 
patients were selected for gefitinib treatment based on 
EGFR mutation status (WJTOG study), patients had lon-
ger progression-free survival (9.2 mo) if  they were treated 
with gefitinib than if  they were treated with cisplatin plus 
docetaxel (6.3 mo) (P < 0.0001)[23]. 
Clinical trials are ongoing for other types of  cancer. An-
other approved inhibitor of  EGFR, erlotinib, which is used 
in a selected patient group with NSCLC, is usually preferred 
to gefitinib. However, although an initial response rate of  
75% has been shown in patients with mutations in EGFR, 
these patients only rarely achieve complete response. In 
half  of  the patients this is due to a T790M mutation in 
EGFR[24]. Though lung tumors might be resistant to erlo-
tinib, metastases of  these tumors to the brain can be sensi-
tive to the drug[25]. Another EGFR inhibitor is lapatinib, 
which in addition to EGFR, inhibits ErbB2[26]. This inhibi-
tor gave good results in Phase Ⅲ ErbB2 positive breast 
cancer trials[27]. Canertinib is an inhibitor of  all EGFR fam-
ily members[28]. Phase Ⅱ studies are ongoing in metastatic 
NSCLC and breast cancer. In addition, many other single 
and multiple EGFR inhibitors are in clinical development. 
The VEGFR/PDGFR family: The PDGFR family 
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Figure 1  Homodimerization or heterodimerization of two epidermal growth factor receptors activates a cascade of tyrosine kinases phosphorylation re-
sulting in increased proliferation and decreased apoptosis. 
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Table 2  Tyrosine kinase inhibitors of the epidermal growth factor receptor tyrosine kinase family
Inhibitor Tyrosine kinase target Neoplasm(s) targeted Clinical status
Gefitinib (Iressa, ZD1839) EGFR Lung, breast Approved
Erlotinib (Tarceva, OSI774)   EGFR Lung Approved
Lapatinib (Tykerb, GW-572016) ErbB1, ErbB2 Breast, RCC, gastric, HN, NSCLC Approved
Canertinib (CI-1033) EGFR, ErbB2, ErbB3, ErbB4 Breast, NSCLC, HN Phase I/Ⅱ
NVP-AEE788 EGFR, ErbB2, VEGFR Solid tumors Phase Ⅱ
XL647 EGFR, ErbB2, VEGFR, EphB4 Cancer Phase Ⅰ
PKI-166 EGFR, ErbB2 Adv solid tumors Phase Ⅰ
SU-11464 ErbB2 Cancer Preclinical
EKB-569 EGFR, ErbB2 NSCLC, colorectal, solid Phase Ⅱ
AG1478 EGFR Nasopharyngeal Preclinical
CP724,714 ErbB2 Breast, adv solid tumors Phase I/Ⅱ
PD-158780 EGFR, ErbB2, ErbB4 Cancer Preclinical
CP-654577 ErbB2 Breast Preclinical
BIBW2992 EGFR, ErbB2 NSCLC, HN, breast Phase Ⅱ
HKI-272 ErbB2 Breast, solid tumors Phase I/Ⅱ
CL-387,785 EGFR, ErbB2 Cancer Preclinical
CP358,774 EGFR HN, ovarian, breast Phase Ⅱ
MP 412 EGFR, ErbB2 NSCLC, breast, HN, pancreatic, prostate Phase Ⅰ
Trk: Nerve growth factor receptor tyrosine kinase; PKC: Protein kinase C; RCC: Renal cell carcinoma; HN: Head and neck cancer; NSCLC: Non small cell 
lung cancer; EGFR: Epidermal growth factor receptor.
Table 1  Single-targeted and multi-targeted inhibitors of cellular tyrosine kinases ABL, SRC and janus kinase family
Inhibitor Tyrosine kinase target Neoplasm(s) targeted Clinical status
Bcr-Abl inhibitors
Imatinib mesylate (STI571) Bcr-Abl, Kit, PDGFRβ CML, ALL, GISTs Approved
Nilotinib (AMN107) BcrAbl, Kit, PDGFRβ CML, Pcp ALL, HS, SM Approved
Tyrphostin AG1024 Bcr-Abl, P-Akt CML (refract to STI571) Preclinical
ON012380 Bcr-Abl CML Phase Ⅰ
Tyrphostin AG957 Bcr-Abl CML Preclinical
Adaphostin Bcr-Abl CML Preclinical
NS-187 Bcr-Abl, Lyn CML, Pcp ALL Preclinical
SRC family inhibitors
Dasatinib (BMS354825) Bcr-Abl, SRC Adult CML, Pcp ALL Approved
SKI-606 Bcr-Abl, SRC Pcp leukemia, breast Phase Ⅰ/Ⅱ
AZD0530 Bcr-Abl, SRC Solid tumors Phase Ⅰ
Lung, liver, colorectal Phase Ⅱ
TG100435 SRC, Lyn, abl, yes, lck, EphB4 Anti-cancer Preclinical
PD166326 Bcr-Abl, SRC, lyn CML Preclinical
PD180970 Bcr-Abl, SRC, Kit CML Preclinical
AZM475271 SRC Pancreatic Preclinical
CGP76030 Bcr-Abl, SRC CML, prost, bone met Preclinical
PP1 FYN, Lck, Kit, Bcr-Abl CML Preclinical
PP2 SRC, Lck, Fyn, Hck Colon Preclinical
AP-23236 SRC Bone metastases Preclinical
PD173955 + 56 BA, Kit, csk, PDGFRβ, EGFR CML Preclinical
SU6656 Scr, Fyn, Yes, Lyn Lymphoma Preclinical
CGP77675 SRC Bone  Preclinical
SU11333 + 36 SRC Breast, colon Preclinical
JAK inhibitors
CP-690 550 JAK3 Immunogenic Preclinical
AG-490 JAK2/3, EGFR Leukemia, glioma Preclinical
WHI-P154 JAK3, Hck, Syk Neural precursor cells Preclinical
WHI-P131 JAK3 Leukemia, GVHD Preclinical
WP-1034 JAK, Stat AML Preclinical
LFM-A13 JAK2, BTK Leukemia Preclinical
BTK: Bruton’s tyrosine kinase; CML: Chronic myeloid leukemia; Pcp: Philadelphia chromosome positive; ALL: Acute lymphoblastic leukemia; GIST: 
Gastrointestinal stromal tumors; HS: Hypereosinophilic syndrome; SM: Systemic mastocytosis; GVHD: Graft-versus-host disease; Cancer: Several cancer 
indications; PDGFR: Platelet derived growth factor receptor; EGFR: Epidermal growth factor receptor.
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is involved in the pathogenesis of  several tumor types. 
PDGFR is important in cellular growth, proliferation, 
differentiation and angiogenesis[29]. FLT3 duplications 
and point mutations are implicated in the pathogenesis 
of  acute myeloid leukaemia (AML)[30]. KIT mutations are 
involved in the pathogenesis of  AML, gastrointestinal 
stromal tumors (GIST) and systemic mast cell disease 
(SMCD)[31]. Multiple PDGFR inhibitors are in clinical de-
velopment for cancer therapy, most of  which are directed 
against several tyrosine kinases. In addition to its activity 
against Bcr-Abl, imatinib also inhibits mutated c-KIT and 
PDGFR. For this reason, it is used for the treatment of  
GIST, where 90% of  the tumors harbor a c-KIT mutation 
and of  the 10% that do not, 30%-50% harbor a mutation 
in PDGFR[32]. Whereas imatinib is effective against the 
juxtamembrane mutated c-KIT in GIST, it has no activ-
ity against active site mutations that occur in AML and 
systemic mastocytosis (SM). Tandutinib (MLN518), which 
was initially developed as a FLT-3 inhibitor, also shows 
activity against wild-type and juxtamembrane mutated and 
active site mutated (D816V) c-KIT[33]. It is being evaluated 
in phase Ⅱ studies for relapsed or refractory AML[34]. An-
other PDGFR kinase inhibitor is leflunomide. In addition 
to PDGFR, it partially inhibits the kinase receptors EGFR 
and FGFR. The drug is being evaluated for prostate and 
glioblastoma multiforme cancer patients in phase Ⅱ and 
Ⅲ trials and for several types of  cancer in preclinical 
phases[3]. Leflunomide is also being used for treatment of  
rheumatoid arthritis[35]. In Table 3, an overview is given of  
single-targeted and multi-targeted PDGFR tyrosine kinase 
inhibitors in different phases of  development.
Several multi kinase inhibitors that are in development 
target the VEGFR family in addition to the PDGFR fam-
ily. The rationale behind this is that tumor survival, growth 
and metastasis depend on tumor cell proliferation and 
angiogenesis, the last of  which is mediated by endothelial 
cell proliferation. Targeting these processes simultaneously 
by blocking RTKs on tumor cells and VEGF activity on 
endothelial cells can be relevant in cancer therapy. Semax-
inib inhibits the tyrosine kinase receptors VEGFR-2, 
c-KIT and FLT-3. The inhibitor showed good results in 
phase Ⅱ AML trials[36]. However, no objective response 
rates were obtained in other types of  cancer. A more se-
lective angiogenesis inhibitor is vatalanib, which inhibits 
VEGFR1, 2 and 3. At higher concentrations the receptors 
PDGFRβ and c-Kit are also inhibited. Clinical studies in 
several types of  cancer have been concluded[37,38]. The in-
hibitor sunitinib targets multiple kinase receptors including 
VEGFR, PDGFR, c-KIT, and FLT-3, thereby resulting in 
both direct antitumor as well as antiangiogenic activity. It is 
approved for progressed GIST after imatinib therapy, for 
intolerated imatinib therapy for GIST and for advanced 
renal cell carcinoma[39]. Another approved tyrosine kinase 
inhibitor for advanced renal cell carcinoma is sorafenib, 
which targets both proliferation and angiogenesis by inhib-
iting c-KIT and Flt-3 on the one hand and VEGFR and 
PDGFR on the other. In addition, it inhibits the serine/
threonine RAF/MEK/ERK pathway[40]. Phase Ⅲ trials 
were performed in NSCLC[41] in which the drug showed 
moderate activity with disease stabilization (median sur-
vival of  2.7 mo) and the drug is in development for several 
other types of  cancer. Its activity is particularly promising 
in hepatocellular carcinoma. The combination of  sorafenib 
and erlotinib showed a good response (28%) and disease 
stabilization (46%) in NSCLC even in patients with K-ras 
mutations, with a median time to progression of  10 mo[42], 
which is thought to be due to simultaneous inhibition of  
multiple signaling pathways, such as the Ras pathway. The 
combination was additive to synergistic in NSCLC cells, 
with the most pronounced effect found in cells with mu-
tant K-ras[43]. This combination is also being evaluated in 
hepatocellular carcinoma for which sorafenib is also regis-
tered[44]. In Table 4, an overview is given of  both approved 
tyrosine kinase inhibitors and tyrosine kinase inhibitors in 
development that are targeted against both the PDGFR 
and the VEGFR tyrosine kinase families. 
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Table 3  Tyrosine kinase inhibitors of the platelet derived growth factor receptor tyrosine kinase family
Inhibitor Tyrosine kinase target Neoplasm(s) targeted Clinical status
Leflunomide (SU101) PDGFRβ, EGFR, FGFR Prostate  cancer Phase Ⅱ/Ⅲ
Lestaurtinib (CEP-701) Flt3, Trk, VEGFR2 Leukemia, pancreatic, AML Phase Ⅱ
Tandutinib (MLN518) Flt3, PDGFRβ, Kit AML Phase Ⅰ/Ⅱ
SU14813 VEGFR2, PDGFRβ, Flt3 Adv malignancies Phase Ⅰ, suspended
XL999 FGFR, VEGFR1/2/3, PDGFRβ, Flt3 Cancer Phase Ⅱ, suspended
VX-322 Flt3, Kit AML Preclinical
SU5614 Flt3 AML, solid tumors Preclinical, suspended
GTP-14564 Flt3 AML Preclinical
KI23819 Flt3 AML Preclinical
Gö6976 Flt3, JAK2 AML Preclinical
AG1296 PDGFRβ, Kit, Flt3 AML Preclinical
PKC412 Kit, PDGFRβ, PKC, Flt3, VEGFR2 Solid tumors Phase Ⅱ
OSI 817 Kit, VEGFR Solid tumors Preclinical
CP-868596 PDGFRβ Adv solid tumors Phase Ⅰ
NSCLC Phase Ⅱ
Trk: Nerve growth factor receptor tyrosine kinase; PKC: Protein kinase C; RCC: Renal cell carcinoma; HN: Head and neck cancer; NSCLC: Non small cell 
lung cancer; PDGFR: Platelet derived growth factor receptor; EGFR: Epidermal growth factor receptor; AML: Acute myeloid leukaemia.
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WHAT’S BETTER: MULTI SINGLE OR A 
SINGLE MULTI?
The considerations to determine whether multiple single 
kinase inhibitors or a single multi kinase inhibitor is pref-
erable in cancer therapy are based on aspects concerning 
efficacy, resistance, pharmacokinetics, selectivity and tu-
mor environment.
Efficacy
Large differences exist in the extent and number of  ex-
pressed tyrosine kinases between different tumor types. 
Whereas in AML (only) 20 different receptors are ex-
pressed, brain tumors may express 50 different recep-
tors[45]. The variability between tumor types is large, but 
tumors of  the same histological type tend to have more 
similar receptor tyrosine kinase profiles, with disease spe-
cific expression, both in number and type of  receptors. 
Müller-Tidow et al[45] postulated that in cancer types 
where relatively few tyrosine kinases are (over)-expressed 
as in AML, the importance of  each kinase might be rela-
tively higher. For this reason, specific targeting of  these 
single kinases, will offer a greater chance of  an effective 
treatment compared with other tumors that have a higher 
number of  alterations in receptor tyrosine kinase expres-
sion. However, this statement only holds when all kinases 
have an equal share in the contribution to carcinogenesis. 
But, also in AML some receptors are relatively highly 
overexpressed compared to others and these seem most 
suited as targets. For cancers with many overexpressed ki-
nases, targeted inhibition of  the important kinases is likely 
to be more effective than randomly inhibiting a couple of  
receptors using a multi inhibitor. The use of  either single 
or multi targeted inhibitors must not depend on the num-
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Table 4  Tyrosine kinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinase families
Inhibitor Tyrosine kinase target Neoplasm(s) targeted Clinical status
Sunitinib (Sutent, VEGFR1/2/3, PDGFRα/β, Kit, GIST (imatinib resist) Approved
SU11248) Flt3, CSF1R, RET Adv RCC Approved
NSCLC Phase Ⅲ
Vandetanib (ZD6474) VEGFR2, EGFR, RET Solid tumors Phase Ⅰ/Ⅱ
Adv NSCLC Approved
Medullary thyroid Phase Ⅱ
Vatalanib (PTK787/ZK222584) VEGFR1/2/3, PDGFRβ, Kit Colorectal, prostate, RCC, MDS, AML, MM Phase Ⅲ
Phase Ⅰ/Ⅱ
Sorafenib (BAY 43-9006) B-Raf, VEGFR2/3, PDGFRβ, Adv RCC Approved
Flt3, Kit, RAF, RET NSCLC Phase Ⅲ
Melanoma, prostate Diff phases
Semaxinib (SU5416) VEGFR2, Kit, Flt3, Stat5, AKT AML Phase Ⅱ
Cediranib (AZD2171) VEGFR1/2/3, PDGFRβ, Kit Solid tumors Phase Ⅰ/Ⅱ/Ⅲ
CEP-7055 VEGFR1/2/3, Flt3 Solid tumors Phase  Ⅰ/Ⅱ
Dovitinib lactate VEGFR1/2, FGFR1/3, PDGFRβ, Multiple myeloma Phase Ⅱ/Ⅲ
(TKI258; CHIR258) Flt3, Kit, CSFR1 
CP-547,632 VEGFR2, FGFR Ovarian, lung Phase Ⅰ/Ⅱ
Pazopanib (GW786034) VEGFR1/2/3, PDGFRα/β, Kit RCC, Approved;
Multiple myeloma; Phase Ⅰ/Ⅱ
solid tumors Phase Ⅰ/Ⅱ
OSI-930 VEGFR, Kit Cancer, anti-angiogenic Phase Ⅰ/Ⅱ
Foretinib (XL-880; GSK 1363089) VEGFR, c-MET HCC, gastric Phase Ⅰ/Ⅱ
KRN-951 VEGFR1/2/3, PDGFRβ, Kit  Adv cancer Phase Ⅰ/Ⅱ
SU10944 VEGFR Solid tumors Preclinical
ZK-CDK VEGFR1/2/3, PDGFRβ, Cdks Breast, prostate Phase Ⅰ/Ⅱ, suspended
Axitinib (AG-13736) VEGFR1/2, PDGFRβ, Kit Solid tumors Phase Ⅱ/Ⅲ
Motesanib diphosphate VEGFR1/2, PDGFRβ, Kit, RET Anti-angiogenic  Phase Ⅱ
(AMG706) GIST (Imatinib resist) Phase Ⅱ
NSCLC Phase Ⅲ
Brivanib (BMS-582664) VEGFR2, FGFR Solid tumors Phase Ⅰ/Ⅱ
PD173074 VEGFR, FGFR Solid tumors, anti-angio Preclinical
Linifanib (M10-963; ABT-869 PDGFRβ, VEGFR2, CSF1R NSCLC, HCC, RCC Phase Ⅱ/Ⅲ
BAY57-9352 VEGFR2/3, PDGFRβ, Kit Anti-angiogenic Phase Ⅰ
SU11657 TELPDGFRβ, VEGFR, Kit, Flt3 CMML Preclinical
Regorafenib (BAY 73-4506) VEGFR-2, Tie-2 RCC; HCC Phase Ⅱ
XL-184 VEGFR-2, c-MET, c-Kit, Tie-2 NSCLC, Glioblastoma, lymphoma Phase Ⅱ
BIBF1120 VEGFR2, PDGFR, FGFR Ovarian Phase Ⅱ
Adv solid tumors Phase Ⅰ
AZD6244 MEK NSCLC, pancreas melanoma Phase Ⅱ
TSU-68 (SU6668) VEGFR2, PDGFRβ, FGFR, Kit Adv solid tumors Phase Ⅰ/Ⅱ/Ⅲ
CMML: Chronic myelomonocytic leukemia; MDS: Myelodysplastic syndromes; MM: Multiple myeloma; HCC: Hepatocellular carcinoma; RCC: Renal cell 
carcinoma; NSCLC: Non small cell lung cancer; PDGFR: Platelet derived growth factor receptor; EGFR: Epidermal growth factor receptor; AML: Acute 
myeloid leukaemia.
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ber of  expressed kinases but on the importance of  par-
ticular kinases in a particular type of  cancer. In the case 
where several kinases are overexpressed and several ap-
pear to contribute to the carcinogenesis, then a single mul-
tikinase inhibitor would be most effective. A high number 
of  RTKs are overexpressed in NSCLC[46]. Although a 
multikinase inhibitor seems to be advantageous because 
of  its ability to inhibit several of  the receptors that are 
overexpressed, it has to be noted that in contrast to the 
data concerning several other cancer types[45], the variabil-
ity between the expression of  RTKs in NSCLC is high. 
This variability includes both the number of  expressed 
kinases (at least 9 in 75%, 18 in more than 50% and more 
than 33 in 25%) and the type of  kinases and also depends 
on the subtype of  the lung tumor. Although in some 
cases EGFR mutations cause tumor pathogenesis, over-
expression of  EGFR and other receptor tyrosine kinases 
is the most important mechanism of  lung carcinogenesis. 
Besides this variability, some receptor tyrosine kinases 
highly increase the risk of  metastasis. In addition to the 
EGFR family, which is known to play an important role in 
metastasis, other receptors such as insulin receptor (INSR) 
and neurotrophic tyrosine receptor kinase 1 (NTRK1) are 
even more important and increase the risk for metastasis 
up to 7-fold[46]. The tyrosine kinase receptors DKFZ1 and 
EPHB6 reduce the risk of  metastasis. For this reason, it 
is important to specifically inhibit the crucial receptor ty-
rosine kinases that increase the metastasis risk and not to 
touch the suppressive ones. This specific inhibition will be 
more difficult using a single multi kinase inhibitor. 
In addition to the variability of  expressed receptor 
tyrosine kinases between tumor types and subtypes, the 
possibility exists that some receptor kinases are tumor 
suppressor genes or that the role of  the same receptor 
tyrosine kinases expressed in various types of  cancer can 
differ. As a consequence, the possibility exists that non-
selective multiple kinase inhibitors can promote cancer 
growth. For example, although its role in cancer is not 
completely elucidated, evidence exists that ErbB4 can 
function as a tumor suppressor gene in breast, prostate 
and kidney epithelia[47]. As a consequence, a tyrosine kinase 
inhibitor like canertinib - which at the moment is evaluated 
in clinical trials for the treatment of  breast cancer -, might 
stimulate rather than suppress tumor growth because it 
non-selectively targets members of  the EGFR family. In 
addition, whereas EPHB6 is highly overexpressed in AML 
and consequently can be assumed to play a role in its carci-
nogenesis, the same receptor reduces the risk of  metastasis 
in NSCLC[45,46]. Besides, the expression of  several receptor 
tyrosine kinases is downregulated in AML[45], which ques-
tions their role as oncogenes.
Summarized, in addition to (receptor) tyrosine kinases’ 
known function of  acting as an oncogene in one setting, 
there is a possibility of  a tumor suppressive role of  these 
proteins in another. This underscores the necessity of  cau-
tion in inhibiting them while there is a risk of  (widely) test-
ing these inhibitors for several types of  cancer. 
Resistance
The use of  tyrosine kinase inhibitors is often accompa-
nied by resistance. This resistance to (receptor) tyrosine 
kinase inhibitors can develop in several ways. Different 
mechanisms are summarized in Table 5. 
In those types of  cancer where resistance is frequently 
caused by a mutation in a tyrosine kinase receptor that 
plays an important role in the carcinogenesis, two single 
inhibitors with a high potency for this kinase might be 
more effective than one inhibitor against this kinase and 
several other kinases. The reason for this is that the muta-
tion decreases the affinity of  the kinase to the inhibitor. 
An example is given by CML, where insensitivity to ima-
tinib most often results from point mutations in the kinase 
domain of  Bcr-Abl[48]. A case of  resistance to imatinib due 
to a mutation in PDGFR in addition to mutation in KIT 
was reported for GIST. However, resistance caused by the 
activation of  another kinase seems unlikely in imatinib re-
sistant leukemic patients, unless there is the possibility of  
resistance induction by activation of  LYN[49-51]. In addition, 
amplification of  Bcr-Abl gene is associated with resistance. 
Resistance can also be caused by differential expres-
sion of  the drug transporters hOCT1 and MDR1 (ABCB1, 
P-glycoprotein), which mediate the active cellular influx 
and efflux transport of  imatinib, respectively[52]. Also 
BCRP (ABCG2) has been reported to be implicated in re-
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Table 5  Resistance mechanism to tyrosine kinase inhibitors
Mechanism Target/drug/disease Ref.
1 (Secondary) mutation of the tyrosine kinase Bcr-Abl in CML, FLT3 in AML, EGFR in NSCLC, 
c-KIT in GIST
[12]
2 Gene amplification and subsequent overexpression of the protein kinase Bcr-Abl in CML + c-KIT in GIST [12]
3a Activation of other signaling pathways PDGFR mutation in c-KIT mutated GIST, MET 
overexpression in EGFR mutated NSCLC
[50]
3b Overexpression of kinases downstream of the kinase LYN in CML
4 Lower intracellular drug concentrations because of:
4a Extracellular sequestration of the inhibitor by binding to α acid glycoprotein PKC412, imatinib [99]
4b Decreased expression or activity of drug influx pumps OCT1, imatinib [52]
4c Increased expression or activity of drug efflux pumps BCRP, P-glycoprotein (imatinib) [51,60]
NSCLC: Non small cell lung cancer; PDGFR: Platelet derived growth factor receptor; EGFR: Epidermal growth factor receptor; CML: Chronic myeloid 
leukemia; GIST: Gastrointestinal stromal tumors;  AML: Acute myeloid leukaemia.
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sistance to imatinib[53]. Binding of  imatinib to a1-acid gly-
coprotein can cause resistance as well as the overexpres-
sion of  Bcl-2 or loss of  Bim and Bad. The latter can be 
overcome by combination therapy with the BH3 mimetic 
ABT-737[54]. The first way to bypass imatinib resistance is 
to develop inhibitors that bind Bcr-Abl with a higher af-
finity and therefore are able to avoid the development of  
resistant leukemic clones. However, it is expected that the 
effect of  these new inhibitors will only be temporary since 
resistance will develop again. Since most resistance mech-
anisms are developed by mutations, it has been hypoth-
esized that a combination of  Bcr-Abl inhibitors, which 
both have different mutation profiles, might be effective 
to prevent the development of  imatinib resistant clones[55]. 
Synergistic effects to imatinib-resistant Bcr-Abl cells have 
been observed in vivo when both nilotinib and imatinib 
were administered[56]. Since mutants arise from the way of  
binding with the inhibitor, a combination of  imatinib or 
nilotinib with dasatinib should give an even more effective 
result. Imatinib and nilotinib bind only to the inactive con-
formation of  Abl while dasatinib binding is independent 
of  the conformation of  Bcr-Abl[10]. It would be even bet-
ter to use a combination of  an ATP competitor (imatinib, 
nilotinib or dasatinib) and a substrate competitor such as 
ON012380 to inhibit each other’s resistance inducing mu-
tants by attacking different parts of  the kinase[57].
In several types of  cancer, resistance is caused by 
means of  overexpression of  the target kinase. In these 
cases inhibiting a kinase downstream of  the tyrosine kinase 
receptor in addition to the target receptor itself  will be ef-
fective because these downstream kinases are not amplified. 
A single multi kinase will be preferred because the sensi-
tivity to the inhibitor is not decreased by amplification. In 
addition, inhibition of  the kinases is not specific for cancer 
cells and will result in toxicity to normal cells. To minimize 
these side-effects it will be better to use a single inhibitor 
instead of  two. 
Fifty percent of  the resistance to gefitinib and erlo-
tinib is caused by a secondary mutation (T790M, D751Y 
or exon 20 insertion) in the EGFR gene[58] and in some 
cases by the multidrug transporter ABCG2[59,60]. K-ras mu-
tation and p-Akt overexpression are considered as resis-
tance mechanisms for erlotinib and gefitinib too[61,62]. Loss 
of  PTEN has not yet been found to be associated with 
p-Akt overexpression or with resistance to gefitinib[62,63]. 
In addition to the resistance mechanisms of  a secondary 
mutation and amplification of  the target kinase, another 
mechanism was found to play a role in the resistance of  
NSCLC to gefitinib and erlotinib. Amplification of  MET 
appeared to be responsible for another 22% of  these 
lung tumors. The shift to this alternative tyrosine kinase 
receptor resulted in the activation of  PI3K/Akt signal-
ing by ErbB3 phosphorylation without the involvement 
of  EGFR and ErbB2[64]. Based on the involvement of  
a second gene in the development of  resistance, the use 
of  combination therapies of  MET inhibitors and EGFR 
inhibitors can offer effective treatment for patients that 
are resistant to gefitinib or erlotinib. In this case, a second 
single tyrosine kinase inhibitor against MET should be ad-
ministered in addition to gefitinib or erlotinib. The same 
approach is used for RAS mutations that are responsible 
for resistance to erlotinib and gefitinib.
It appears that resistance in one cancer type can be 
caused by several resistance mechanisms. In case of  a sec-
ondary mutation in EGFR, a second inhibitor of  EGFR 
with a different matching profile would be preferable. 
However, in case of  resistance mediated by overexpres-
sion of  MET, this approach wouldn’t induce any effect.
Regarding the reduced intracellular drug concentra-
tion as a mechanism for resistance, it depends on the type 
of  cancer and the tumor cell characteristics which type 
of  treatment will be most effective. A single multi kinase 
inhibitor can be very effective, but if  it becomes the target 
of  extracellular sequestration or substrate of  an efflux 
transport pump, it will be lost. The same holds for the sin-
gle inhibitors, however, in this case, more flexibility exists 
thanks to the possibility of  switching to other single kinase 
inhibitors when resistance by this mechanism is detected. 
It is believed that several mutations and amplifications 
of  genes that cause primary resistance are already present 
before treatment is started. These mutant receptor kinases 
remain sensitive for particular tyrosine kinase inhibitors. 
For example imatinib resistant c-KIT remains sensitive to 
PKC412 while AP23464 is very potent in CML resistant 
to imatinib[65,66]. In addition, PD166326 shows increased 
activity against the SRC family member LYN[14]. For this 
reason, it is very important to identify the mutation by 
which the kinase is activated in order to be able to decide 
the most effective type of  therapy that is insensitive to re-
sistance development.
Pharmacokinetics 
The pharmacokinetics of  a drug is described by its ab-
sorption, distribution, metabolism and excretion (ADME), 
which determines the bioavailability of  the drug. The 
pharmacokinetic properties of  tyrosine kinase inhibitors 
are also associated with their molecular weight, hydro-
phobicity/hydrophilicity, hydrogen bonding and active 
transport; CYP enzymes and various transporters also 
play a major role[67-68]. Regarding these properties, a single 
multi inhibitor will be preferred to two single inhibitors 
if  one of  the last is a substrate for a drug transport pump 
or is metabolised. Such a drug will become second choice 
when its pharmacokinetic properties are worse. A possible 
problem associated with the administration of  two single 
inhibitors is that the drug metabolism of  the one single 
drug can interfere with the metabolism of  the other. In 
that case, a single multi-kinase inhibitor is preferred; oth-
erwise there is no preference. Although much is known 
about the pharmacokinetics of  tyrosine kinase inhibitors, 
a complete overview is beyond the scope of  this paper 
and only some examples will be given.
Li et al[69] compared the pharmacokinetics of  the me-
tabolism of  two approved EGFR inhibitors gefitinib and 
erlotinib. It was shown that the metabolic clearance of  
gefitinib was higher than the metabolic clearance of  erlo-
tinib. In addition, the importance of  various cytochrome 
P450 enzymes involved in the metabolism was different 
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between both inhibitors[69]. However, to determine and 
compare the pharmacokinetic properties of  tyrosine ki-
nase inhibitors in a predictive way in order to show a pref-
erence for one of  the types is very difficult. First, tyrosine 
kinase inhibitors that reached the market during the last 
five years have a satisfactory to good bioavailability. Sec-
ond, regardless of  the type of  inhibitor, pharmacokinetics 
of  a particular drug can differ between patients because 
of  differences in metabolism and can change over time in 
the same patient. In this context, additional factors like the 
influence of  smoking on the metabolism of  the inhibitors 
play a role too. By comparing the pharmacokinetics of  
erlotinib in smokers and non-smokers, it has been shown 
that in current smokers the metabolic clearance of  the in-
hibitor is increased[70].
Regarding imatinib a large interindividual variation 
was found which is related to efficacy of  the drug[71]. This 
variation was related to alpha-acid glycoprotein binding, 
while a 22% reduction in clearance was observed in het-
erozygous compared with wild-type patients correspond-
ing to BCRP (ABCG2 c.421C>A (P < 0.05). This large 
variation was earlier related to the expression of  BCRP 
and P-glycoprotein[72,73]; e.g. in mice with a BCRP knock 
out the clearance was increased while the accumulation in 
brain was also increased[73]. SNPs in the BCRP gene were 
also associated with toxicity of  sunitinib and gefitinib, 
possibly due to aberrant pharmacokinetics[74,75].
Regarding pharmacokinetics, it is difficult to predict 
which type of  inhibitor will show the most optimal results 
in cancer patients. This is due to similarities in physico-
chemical properties between tyrosine kinase inhibitors 
and interindividual differences in drug metabolism. In ad-
dition, small differences in inhibitors that are independent 
of  the inhibitor type can make them, for example, sub-
strate for a drug transport pump. So, in order to determine 
the most optimal TKI type, comparative pharmacokinetic 
studies for particular TKIs in a specific setting have to be 
performed and will result in different conclusions depend-
ing on the investigated inhibitors and the setting.
Selectivity
The tyrosine kinase domain of  protein tyrosine kinases 
consists of  an N-terminal lobe and a C-terminal lobe, 
the last of  which is the binding site for downstream pro-
teins. The ATP binding site is in the cleft between the 
two lobes[76]. It turned out to be difficult to design small 
molecule inhibitors that specifically attack the substrate 
binding site[77]. One of  the few examples is the Bcr-Abl in-
hibitor ON012380, which because of  its possibility to bind 
the substrate binding site of  Bcr-Abl, is very effective in 
inhibiting the kinase domain of  mutated Bcr-Abl (10 fold 
more potent than imatinib)[57]. In order to obtain selectiv-
ity, tyrosine kinase inhibitors are designed to specifically 
attack the ATP binding site of  tyrosine kinases. Although 
the ATP binding site is highly conserved, selectivity of  ty-
rosine kinase inhibitors is realized by exploiting the proxi-
mal regions of  the ATP binding site. Hydrogen bonds of  
the adenine region are used by inhibitors and increase their 
potency. The sugar region is used for selectivity in EGFR 
inhibitors because of  a different amino acid residue com-
pared to the other receptors[78]. The hydrophobic pocket 
(also called the selectivity pocket) and channel, which is not 
used by ATP-binding, play an important role in inhibitor 
selectivity and binding affinity, respectively. The phosphate 
binding region itself  can be used to improve selectivity[79]. 
In addition to the substrate binding site and the ATP 
binding site of  the tyrosine kinase domain, a new target 
useful in drug development might be the juxtamembrane 
region. 
This region is located between the transmembrane 
helix and the kinase domain and autoinhibits the catalyt-
ic activity of  receptor tyrosine kinases. Because of  lack 
of  sequence similarity amongst juxtamembrane regions 
between different receptor tyrosine kinase families, this 
region has been suggested to be a good target to obtain 
specificity and increased affinity[80].
Because it is difficult to design inhibitors that specifi-
cally inhibit single kinases, it is inevitable that other kinas-
es, at least to a lower degree, are inhibited as well, resulting 
in side effects. In this way, multi kinase inhibitors are less 
specific and might consequently lead to more side effects. 
In addition to the extent of  selectivity between tyro-
sine kinases, regarding the side effects, it is also important 
to focus on selectivity for tumor cells compared to nor-
mal cells. An inhibitor like gefitinib is directed against a 
specific mutation, which only occurs in tumor cells. Non-
small-cell lung cancer patients are selected for gefitinib 
and erlotinib based on their mutational status. Deletion 
mutations in EGFR exon 19 and EGFR L858R point mu-
tation, which are associated with a never smoking history, 
female sex and Asian ethnicity, are predictive of  response 
to these tyrosine kinase inhibitors[81]. However, if  the re-
sistance caused by MET overexpression is attacked by a 
MET inhibitor, this approach might lead to many side ef-
fects because this inhibitor will inhibit MET in both nor-
mal and tumor cells. So, the extent of  side effects depends 
on the degree of  targeted therapy.
In order to avoid cross reactivity of  tyrosine kinase 
inhibitors, Fernández et al[82] obtained selectivity of  kinase 
inhibitors for tyrosine kinases by comparing kinase de-
hydron patterns since dehydrons - the underdehydrated 
backbone hydrogen bonds of  a kinase - are not conserved 
between kinases[82].
It has been suggested that the most important condi-
tion for an inhibitor to achieve specificity for a particular 
kinase, is the ability to adapt to multiple conformational 
states of  the enzyme. This ability seems to be more im-
portant than differences in sequence of  the kinase domain 
or differences in interactions with binding site residues[83]. 
This mechanism of  specificity is shown by erlotinib, which 
is suggested to be dependent on the recognition and high 
affinity binding of  many conformations of  EGFR. An-
other specificity mechanism dependent on conformation is 
shown by imatinib, which shows highly specific inhibition 
of  PDGFR, c-KIT and Abl. Whereas SRC is phylogeneti-
cally less divergent from Abl than PDGFR and c-KIT are, 
imatinib shows no inhibition of  SRC. This is explained by 
specific inhibition of  the inactive protein conformation 
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that is unique for PDGFR, c-KIT and Abl. Another exam-
ple of  a specificity mechanism is that of  dasatinib, which 
is suggested to inhibit both Abl, c-KIT, SRC and LCK 
because of  its ability to recognize multiple conformational 
states of  many different targets[83]. The systematic analysis 
of  crystal structures of  tyrosine kinases is suggested to be 
useful in the design of  more potent and selective tyrosine 
kinase inhibitors[67].
To increase potency and to minimize side-effects, it 
is essential to design tyrosine kinase inhibitors that selec-
tively block the tyrosine kinase or kinases that are involved 
in the aberrant signaling. For the purpose of  finding selec-
tivity of  the tyrosine kinase inhibitors several mechanisms, 
like differences in sequences, kinase dehydron patterns 
and conformation states of  the kinases are investigated. 
Tumor microenvironment
Tumors are not built up solely of  tumor cells. An impor-
tant part consists of  connective tissue or stroma, made 
up of  stromal cells and extracellular matrix, which is pro-
duced by these cells. Examples of  stromal cells are fibro-
blasts, endothelial cells and macrophages. Stromal cells 
also play an important role in the carcinogenesis, where 
they are characterized by upregulation or induction of  
growth factors and their receptors, adhesion molecules, 
cytokines, chemokines and proteolytic enzymes[84,85]. 
In order to discuss a possible choice between single 
multi kinase inhibitors and multiple single kinase inhibi-
tors, one has to compare cancer cells and stromal cells and 
to look at different types of  tumor stroma. The receptor 
associated tyrosine kinases VEGFR-1 and VEGFR-2 on 
endothelial and tumor cells play a central role in the pro-
motion of  cancer by their involvement in angiogenesis. 
Inhibition of  these receptors by, for example, the tyrosine 
kinase inhibitors sunitinib, vatalanib and sorafenib has led 
to good results in cancer therapy. Another important ty-
rosine kinase is FAK, which is required for the activity of  
integrin and growth factor receptors in endothelial cells 
and fibroblasts. FAK regulates cellular adhesion, migration 
and survival. Inhibition of  FAK could be a good way to 
prevent survival of  these tumor stromal cells. In addition, 
the growth factors TGF-β, PDGF and FGF2 secreted by 
cancer cells transform normal fibroblasts into tumor as-
sociated fibroblasts, which make their receptors a suitable 
target for inhibition by tyrosine kinase inhibitors[85]. Fi-
nally, the EPH tyrosine kinase receptors have been shown 
to be important in tumor cells and tumor stroma by medi-
ating cell-cell interactions[86]. Although VEGFR, PDGFR 
and EPHR are important targets on both tumor cells 
and tumor stroma cells, kinases like FAK only function 
in stromal cells and other oncogenes often only function 
in tumor cells. Regarding this difference in gene expres-
sion between tumor cells and tumor stromal cells, a multi 
kinase inhibitor directed against a receptor tyrosine kinase 
in cancer cells, might not efficiently target this tyrosine 
kinase in tumor stromal cells, but it might target another 
one. 
A complication might be the different composition 
of  stroma between tumors. Whereas the tumor cells in 
glioblastoma are kept together primarily by the blood ves-
sels surrounding them, the tumor stroma in other tissues 
often consists of  “fibroblastic connective tissue”. In the 
first case, the stroma is made up almost entirely of  cellular 
components, the most important of  which are the endo-
thelial cells. In the second case, the stroma consists of  a 
few myofibroblasts, smooth muscle cells or pericytes and 
a lot of  extracellular matrix specific for the type of  cell 
by which it is produced. The type of  cell is dependent on 
the structure of  the host tissue[87]. The differences in both 
tumor cell types and the composition of  the extracellular 
matrix may require different strategies to inhibit tumor 
stroma. Furthermore, tumor-associated fibroblasts of  
different tissues have significant differences in their gene 
expression. Differences between stroma cells even exist in 
a single region[85,88].
In addition to fibroblasts and endothelial cells, tumor 
stroma consists of  immune cells. The infiltration of  mac-
rophages and T cells to the tumor may mean both pro and 
anti-tumor survival, which depends on the expression of  
particular chemokines[85,89,90]. The role of  dendritic cells is 
still ambiguous[85]. Neutrophils are suggested to reduce tu-
morigenicity and natural killer cells inhibit the progression 
to metastasis[91,92]. So, inhibition of  immune cells can also 
cause harm depending on the type of  cell being inhibited 
and on the moment of  immunologic escape. Many differ-
ent settings and tumor characteristics make it difficult to 
prefer one kind of  inhibitor above the other. It becomes 
even more complicated when metastasised disease has to 
be treated since metastases can contain either stromal cells 
and tumor cells with the same character or stromal cells 
of  the new host tissue[93,94]. For some cancers it can be ef-
fective to use a multi kinase inhibitor, which both attacks 
tumor cells and tumor stromal cells efficiently, whereas an-
other type of  cancer needs separate inhibitors for the tu-
mor and stromal cells because of  different tyrosine kinase 
expression. Furthermore, it might turn out that for at least 
some types of  cancer the role of  tyrosine kinase(s) (recep-
tors) is relatively less prominent in stromal tumor cells 
than their role in cancer cells. In this regard, the important 
role fulfilled by chemokines and their receptors, including 
responsibility for leukocyte infiltration and angiogenesis 
has to be considered[85]. Other crucial targets for therapy 
are CD105, TEM8, αvβ3 integrins, PMSA, Tenascin C, 
FAPα, MMPs, uPA and CAIX[84]. At the moment, drugs 
in development are designed to target this large diversity 
of  molecules and receptors. 
From practice, VEGFR has turned out to be a very 
important target and can well be inhibited by using multi 
targeted single inhibitors. EPHR is another important tar-
get to develop inhibitors against, possibly in combination 
with VEGFR. The importance of  other tyrosine kinases 
of  stromal cells in different tumor settings and the best 
way to inhibit them needs further investigation. 
Toxicity
Another consideration in the choice between multiple 
single kinase inhibitors or a single multi-kinase inhibitor 
is the toxicity of  these compounds alone and in com-
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bination. In general the same considerations as for any 
drug have to be taken into account: is toxicity acceptable 
compared to the observed antitumor efficacy? However, 
kinase inhibitors have specific toxicities, either related to 
the primary target kinase(s), an off-target effect or caused 
by a specific metabolite of  the kinase inhibitor. Therefore 
toxicity profiles of  each new drug have to be determined 
before using them in combination. 
EGFR tyrosine kinase inhibitors, such as gefitinib and 
erlotinib cause a typical skin toxicity described as “acne-
iform” rash, which is dose dependent. In a recent study 
erlotinib induced rash was characterized more in detail 
and it appeared to be different from acne vulgaris and was 
characterized as inflammation of  hair follicles, with infil-
tration of  TRAIL-positive dendritic cells[95]. For several 
other specific tyrosine kinase inhibitors, such as imatinib, 
cardiac toxicity has also been found in a substantial num-
ber of  patients[96]. This toxicity became apparent in the 
post-approval phase since this type of  kinase inhibitors 
were usually not screened for cardiotoxicity.
In contrast to the general belief  during early develop-
ment of  kinase inhibitors, these compounds also exhibit 
classical toxicities such as diarrhea and myelotoxicity, 
although to a different extent and with different deter-
minants e.g. EGFR tyrosine kinase inhibitors also display 
diarrhea which for gefitinib could be related to polymor-
phisms in EGFR (191 C/A, -216 G/T and R497K)[97]. 
The toxicity of  erlotinib is also related to its metabolism 
by cytochrome P450 3A4 which is induced in smokers 
compared to non-smokers[70]. Therefore care has to be 
taken that in case of  e.g. erlotinib, combination drugs, ei-
ther another tyrosine kinase inhibitor or a cytotoxic drug, 
do not inhibit erlotinib metabolism, or if  so, the doses 
have been optimized. In case of  combining two selective 
kinase inhibitors, toxicity of  each compound is usually 
well characterized and this will help to predict toxicity of  
the combination. 
Special care has to be taken when drugs targeting neo-
angiogenesis are being used either alone or in combina-
tion. Since tumors are usually driven by mutations in more 
than one signaling pathway, this has led to the design of  
multi-kinase inhibitors, which are by definition not selec-
tive and hence may also affect signaling pathways in nor-
mal tissues. In the early development of  VEGR tyrosine 
kinase inhibitors, it became clear they can exhibit serious 
vascular problems, which was first shown for SU5416[98]. 
The next generation, including sunitinib and sorafenib, 
showed a much more acceptable toxicity profile, although 
cardiac toxicity can be a problem. Usually this is an off-
target toxicity. Sunitinib, an inhibitor of  VEGFR, PDGFR 
and c-kit, was also shown to inhibit AMP-activated pro-
tein kinase (AMPK), which led to a disturbance of  the 
metabolic homeostasis in the heart[96], possibly accounting, 
at least in part, for sunitinib induced cardiotoxicity. Hence 
from this perspective multi-kinase inhibitors may be more 
likely to account for cardiovascular toxicity. Therefore 
combinations of  two specific kinase inhibitors may be 
preferable. Next, it will be advisable to screen novel multi-
kinase inhibitors for off-target toxicity such as cardiac tox-
icity, during preclinical development and include careful 
monitoring in early clinical development.
CONCLUSION
The essence of  any therapy is to specifically attack a tumor 
based on the difference in genetic background between 
tumor and normal cells. Targeted therapy focuses on dif-
ferences in signaling pathways driving the growth of  tu-
mors. However, these pathways are disturbed to a different 
extent as a reflection of  the diversity in genetics among 
individuals, hence hitting one target is unlike to cure can-
cer, and therefore attacking more pathways increases the 
chance of  success and bypassing resistance. However, the 
most effective way of  cancer treatment by using tyrosine 
kinase inhibitors is to consider each patient/tumor individ-
ually and to determine the strategy that specifically targets 
the consequences of  altered (epi)genetics of  the tumor, 
with an acceptable toxicity. This strategy might result in 
treatment by a single multi-kinase inhibitor for one patient, 
whereas for other patients this means treatment by a com-
bination of  single kinase inhibitors. 
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